← Eichor
Condition: Pdac Synced from ClinicalTrials.gov · July 28, 2026

Recruiting studies: Pdac

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

A Study to Evaluate INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation
Phase 1 · 34 location(s) · Incyte Corporation · NCT06179160Austrian Registry for Evaluation of Treatment Patterns and Outcome in Patients With Advanced Pancreatic Ductal Adenocarc
Phase N/A · 12 location(s) · Medical University of Graz · NCT05526443NALIRI-XELOX+AK104 for First-line Treatment of Advanced PDAC
Phase 2 · 1 location(s) · Cancer Institute and Hospital, Chinese Academy of Medical Sc · NCT06405490Using 18F-FAPI PET to Detect Metastatic Disease in Patients That Have Pancreatic Ductal Adenocarcinoma (PDAC)
Phase 3 · 15 location(s) · SOFIE · NCT07217717A Study Evaluating the Efficacy of 5-FU + NALIRI and 5-FU + NALIRINOX for PDAC (NALPAC)
Phase 2 · 13 location(s) · Belgian Group of Digestive Oncology · NCT05472259Pancreatic Cancer and Synchronous Liver Metastases Resection Following Neoadjuvant FOLFIRINOX
NA · 1 location(s) · Laval University · NCT06349278Phase I Study of JFI447 [68Ga]Ga-DFC413 and Comparison to FFG233 [68Ga]Ga-NNS309 in Patients With Solid Tumors
Phase 1 · 1 location(s) · Novartis Pharmaceuticals · NCT07630961AVA6103 in Subjects With Locally Advanced or Metastatic Selected Solid Tumors
Phase 1 · 3 location(s) · Avacta Life Sciences Ltd · NCT07454642IN10018 in Combination With RNK08954 for the Treatment of KRASG12D Mutation-Positive Locally Advanced or Metastatic Soli
Phase 1/Phase 2 · 14 location(s) · InxMed (Shanghai) Co., Ltd. · NCT07441174Personalized First-line Chemotherapy Choice in Advanced Pancreatic Adenocarcinoma Using Transcriptomic Signatures
NA · 7 location(s) · Institut Curie · NCT05475366Autologous CAR-T Cells Targeting B7-H3 in PDAC
Phase 1 · 1 location(s) · UNC Lineberger Comprehensive Cancer Center · NCT06158139Master Protocol of TCR-modified T Cell Therapy Targeting HLA-restricted KRAS Antigen Administered in Adult Patients With
Phase 1/Phase 2 · 10 location(s) · Anocca AB · NCT07145450A First-in-Human Trial of BLU-924 (SAR449336) in Advanced Solid Tumors Harboring KRAS Mutations
Phase 1/Phase 2 · 1 location(s) · Blueprint Medicines Corporation · NCT07629960A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Pancreatic Cancer
Phase 2 · 19 location(s) · Verastem, Inc. · NCT07644559AI-powered Early Detection for Pancreatic Cancer Via Non-contrast CT in Opportunistic Screening Cohort
Phase N/A · 3 location(s) · Changhai Hospital · NCT06638866PTM-101 in Pancreatic Ductal Adenocarcinoma (PDAC)
Phase 1 · 6 location(s) · PanTher Therapeutics · NCT06673017Dual-Targeting CAR-NK Cells Targeting Mesothelin (MSLN) and MUC1 in Advanced Pancreatic Ductal Adenocarcinoma
Phase 1/Phase 2 · 1 location(s) · Beijing Biotech · NCT07480928M0324 as Monotherapy and in Combination With Pembrolizumab or Chemotherapy in Participants With Selected Advanced Solid
Phase 1 · 5 location(s) · EMD Serono Research & Development Institute, Inc. · NCT07166601A Clinical Trial Testing the Safety of Pumitamig (an Investigational Drug) and How Well it Works When Combined With Chem
Phase 2 · 24 location(s) · BioNTech SE · NCT07255404A Prospective Registry for Patients at High-Risk for Pancreatic Cancer
Phase N/A · 1 location(s) · Mayo Clinic · NCT06151223Volatile Organic Compound Assessment in Pancreatic Ductal Adenocarcinoma
Phase N/A · 1 location(s) · Imperial College London · NCT05727020Basal-like PDAC Treated With Gemcitabine, Erlotinib, and Nab-paclitaxel
Phase 1/Phase 2 · 1 location(s) · UNC Lineberger Comprehensive Cancer Center · NCT06483555A Study to Evaluate the Safety, Tolerability, and Efficacy of BMS-986523 Alone and in Combination With Anti-Cancer Agent
Phase 1/Phase 2 · 8 location(s) · Bristol-Myers Squibb · NCT07223047To Evaluate the Preliminary Efficacy of Our Digitally Enhanced CHW-led Intervention in Newly Diagnosed PDAC
NA · 1 location(s) · Loma Linda University · NCT07591571A Study to Learn About Study Medicine ALTA3263 in Adults With Advanced Solid Tumors With KRAS Mutations
Phase 1 · 12 location(s) · Alterome Therapeutics, Inc. · NCT06835569Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C M
Phase 1/Phase 2 · 53 location(s) · Revolution Medicines, Inc. · NCT06128551Prediction of Neoadjuvant Chemotherapy Response in Pancreatic Cancer
Phase N/A · 1 location(s) · City of Hope Medical Center · NCT07226154Computed Tomography in Diagnosing Patients With Pancreatic or Hepatobiliary Cancer
NA · 1 location(s) · M.D. Anderson Cancer Center · NCT02361320A Noninvasive and Screening miRNA Signature for Gastrointestinal Cancer
Phase N/A · 1 location(s) · City of Hope Medical Center · NCT07224750Study of TJ033721 (Givastomig) in Subjects With Advanced or Metastatic Solid Tumors
Phase 1 · 21 location(s) · I-Mab Biopharma US Limited · NCT04900818
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.